Insider Selling: Neurocrine Biosciences (NASDAQ:NBIX) CFO Sells $363,289.20 in Stock

Posted by Brian Himes on Sep 18th, 2026

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) CFO Matt Abernethy sold 2,311 shares of Neurocrine Biosciences stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $157.20, for a total transaction of $363,289.20. Following the sale, the chief financial officer owned 42,808 shares of the company’s stock, valued at $6,729,417.60. The trade was a 5.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Neurocrine Biosciences Trading Up 1.6%

Shares of NBIX stock opened at $151.83 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $122.14 and a twelve month high of $186.12. The stock has a market capitalization of $15.43 billion, a price-to-earnings ratio of 22.26, a P/E/G ratio of 0.70 and a beta of 0.38. The stock has a fifty day simple moving average of $162.42 and a two-hundred day simple moving average of $152.00.

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, topping the consensus estimate of $1.65 by $1.20. The firm had revenue of $959.00 million during the quarter, compared to analysts’ expectations of $891.16 million. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The company’s revenue was up 39.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.65 EPS. Research analysts predict that Neurocrine Biosciences, Inc. will post 7.26 EPS for the current fiscal year.

Institutional Investors Weigh In On Neurocrine Biosciences

Institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its stake in Neurocrine Biosciences by 10.6% in the first quarter. Bank of America Corp DE now owns 583,827 shares of the company’s stock valued at $76,913,000 after acquiring an additional 55,723 shares during the last quarter. ABN AMRO Bank N.V. bought a new stake in Neurocrine Biosciences during the second quarter worth $2,510,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Neurocrine Biosciences during the fourth quarter worth $1,866,000. Summit Global Investments acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at $4,959,000. Finally, Focus Partners Advisor Solutions LLC acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at $1,927,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on NBIX. Guggenheim upped their target price on Neurocrine Biosciences from $200.00 to $222.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Canaccord Genuity Group raised their price target on shares of Neurocrine Biosciences from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Citigroup lifted their price objective on shares of Neurocrine Biosciences from $249.00 to $253.00 and gave the company a “buy” rating in a research note on Thursday, September 3rd. Morgan Stanley upped their price objective on shares of Neurocrine Biosciences from $182.00 to $183.00 and gave the company an “equal weight” rating in a report on Friday, September 11th. Finally, Sanford C. Bernstein initiated coverage on shares of Neurocrine Biosciences in a research note on Friday, May 22nd. They issued an “outperform” rating and a $221.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $201.09.

View Our Latest Stock Report on Neurocrine Biosciences

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company develops therapies for conditions with significant unmet medical needs, using expertise in neuroscience and endocrine biology.

Its primary commercial product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.